申请人:Cornell University
公开号:US10689366B2
公开(公告)日:2020-06-23
Provided herein are bifunctional compounds that inhibit MALT1 and/or promote targeted ubiquitination for the degradation of MALT1. In particular, provided are compounds that can bind MALT1, a protein whose activity is responsible for constitutive NF-KB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)), and can assist in its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon, VHL), which can ubiquitinate MALT1, marking it for proteasome degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating cancer with the bifunctional compounds, methods of promoting the degradation of MALT1, and methods of binding E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.
本文提供了抑制 MALT1 和/或促进靶向泛素化以降解 MALT1 的双功能化合物。特别是,所提供的化合物可结合 MALT1(其活性在某些癌症(如活化 B 细胞弥漫性大 B 细胞淋巴瘤(ABC-DLBCL))中负责组成型 NF-KB 信号转导的蛋白质),并可通过招募 E3 泛素连接酶(如 Cereblon、VHL)协助其降解,该连接酶可泛素化 MALT1,将其标记为蛋白酶体降解。还提供了包含双功能化合物的药物组合物、用双功能化合物治疗癌症的方法、促进MALT1降解的方法,以及通过施用本文所述化合物或组合物在受试者体内结合E3泛素连接酶活性的方法。